Several derivatives of pyrido[2,3-d]pyrimidine have shown promising EGFR inhibitory effects II–IV, as well as activity against resistant mutations VI–VII [20,53,54,55,56,57] (Figure 1), making them good candidates for developing next-generation inhibitors effective against mutant EGFR in cancer drug development [58,59,60,61]. This evidence concerns the gene EGFR and cancer.